VRD
VC Fund
Heidelberg, Germany
VRD is a VC fund in Heidelberg focused on Food and Beverage and Fitness. VRD operates as a family office committed to the long-term protection and enhancement of its invested assets. The organization focuses on investing in companies that demonstrate significant growth potential and are led by driven management teams. It represents a family office associated with a longstanding entrepreneurial family.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries VRD invests in
Stages VRD invests in
Countries VRD invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $5.9M–$11M
- Series H
- $2.4M–$4.7M
Investment Focus
Industry
- Food and Beverage 2 (20%)
- Fitness 1 (10%)
- E-Commerce 1 (10%)
- Health Care 1 (10%)
- Biotechnology 1 (10%)
Stage
- Seed 3 (30%)
- Series A 1 (10%)
- Series H 1 (10%)
- Funding Round 1 (10%)
- Venture - Series Unknown 1 (10%)
Country
- Germany 2 (20%)
- Australia 1 (10%)
- United Kingdom 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Abe Abe Gong
Co-Founder & CEO
|
Co-Founder & CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| SUSHI Bikes has developed the perfect e-bike for modern urban people. | Seed / Jul 12, 2023 | ||
| Mighty Pea is a pea milk producer, which uses yellow split peas in the creation of its beverages. | $5.9M / Seed / Dec 08, 2021 | ||
| Many years in the making, Lyre’s exquisite range of lovingly crafted alcohol-free, classic spirits was borne from a quest to make the impossible possible. To provide an alternative to those who don’t wish to imbibe alcohol, but still wish to enjoy the mirth, merriment and social intercourse of an evening soiree or shindig. But this is not justany alternative. Every Lyre’s spirit looks, tastes and sashays around the palate just like the original. And yet, the absence of giggle juice enables revellers to remain clear-headed, of good cheer and in fine fettle to pursue whatever tickles their fancy the following day. Lyre’s – the finest range of non-alcoholic classic spirits the world has ever seen. | $26.8M / Series A / Nov 15, 2021 | ||
| Many years in the making, Lyre’s exquisite range of lovingly crafted alcohol-free, classic spirits was borne from a quest to make the impossible possible. To provide an alternative to those who don’t wish to imbibe alcohol, but still wish to enjoy the mirth, merriment and social intercourse of an evening soiree or shindig. But this is not justany alternative. Every Lyre’s spirit looks, tastes and sashays around the palate just like the original. And yet, the absence of giggle juice enables revellers to remain clear-headed, of good cheer and in fine fettle to pursue whatever tickles their fancy the following day. Lyre’s – the finest range of non-alcoholic classic spirits the world has ever seen. | $6.9M / Seed / May 04, 2021 | ||
| Many years in the making, Lyre’s exquisite range of lovingly crafted alcohol-free, classic spirits was borne from a quest to make the impossible possible. To provide an alternative to those who don’t wish to imbibe alcohol, but still wish to enjoy the mirth, merriment and social intercourse of an evening soiree or shindig. But this is not justany alternative. Every Lyre’s spirit looks, tastes and sashays around the palate just like the original. And yet, the absence of giggle juice enables revellers to remain clear-headed, of good cheer and in fine fettle to pursue whatever tickles their fancy the following day. Lyre’s – the finest range of non-alcoholic classic spirits the world has ever seen. | $9M / Seed / May 01, 2021 | ||
| Many years in the making, Lyre’s exquisite range of lovingly crafted alcohol-free, classic spirits was borne from a quest to make the impossible possible. To provide an alternative to those who don’t wish to imbibe alcohol, but still wish to enjoy the mirth, merriment and social intercourse of an evening soiree or shindig. But this is not justany alternative. Every Lyre’s spirit looks, tastes and sashays around the palate just like the original. And yet, the absence of giggle juice enables revellers to remain clear-headed, of good cheer and in fine fettle to pursue whatever tickles their fancy the following day. Lyre’s – the finest range of non-alcoholic classic spirits the world has ever seen. | $11.2M / Seed / Sep 25, 2020 | ||
| Lophius Biosciences is a young biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases. The company is also offering custom-made services in the area of cell based bioactivity and quality tests for pharmaceutical agents. The core competencies of Lophius Biosciences are in the area ofImmunology and T-cell diagnostics.Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics. | $2.4M / Series H / Mar 18, 2017 | ||
| Lophius Biosciences is a young biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases. The company is also offering custom-made services in the area of cell based bioactivity and quality tests for pharmaceutical agents. The core competencies of Lophius Biosciences are in the area ofImmunology and T-cell diagnostics.Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics. | $4.7M / Series H / Jul 26, 2016 | ||
| Lophius Biosciences is a young biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases. The company is also offering custom-made services in the area of cell based bioactivity and quality tests for pharmaceutical agents. The core competencies of Lophius Biosciences are in the area ofImmunology and T-cell diagnostics.Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics. | $2.8M / Venture - Series Unknown / May 08, 2014 | ||
| See all 10 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does VRD invest in?
VRD invests primarily in Food and Beverage, Fitness and E-Commerce startups, most often at Seed and Series A stage. Most of the 10 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does VRD invest in?
VRD typically joins rounds of $5.9M–$11M at Seed and $2.4M–$4.7M at Series H. These are whole funding-round sizes, not VRD's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds VRD took part in.
How do I contact VRD?
Public channels for VRD include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at VRD?
The team at VRD includes Abe Abe Gong (Co-Founder & CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
